July may not have seen any big-ticket deals — i.e. deals in excess of US$ 1 billion — in the pharma and biotech space. Yet, deal making remained robust last month as well.
Companies like Novartis, Roche, Lilly and Sanofi bolstered their R&D pipelines by striking deals which may result in billion-dollar payouts if they achieve their milestones.
However, major investments were announced in the manufacturing and contract services arena which indicate that pharma job creation could be heading back to the United States.
Trump’s tax cuts make Pfizer announce major US manufacturing investment
Earlier this year, President Donald Trump announced a reduction in the US corporate tax rate from 35 percent to 21 percent. The tax cuts were designed to promote employment and grow manufacturing in the United States.
